Benitec Biopharma (NASDAQ:BNTC) Director Suvretta Capital Management, L Buys 16,836 Shares

Benitec Biopharma Limited (NASDAQ:BNTC) Director Suvretta Capital Management, L bought 16,836 shares of the firm’s stock in a transaction that occurred on Friday, December 26th. The stock was purchased at an average cost of $13.10 per share, with a total value of $220,551.60. Following the completion of the purchase, the director directly owned 9,634,395 shares of the company’s stock, valued at $126,210,574.50. This represents a 0.18% increase in their position. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Suvretta Capital Management, L also recently made the following trade(s):

• On Monday, December 29th, Suvretta Capital Management, L purchased 77,387 shares of Benitec Biopharma stock. The shares were purchased at an average cost of $13.44 per share, for a total transaction of $1,040,081.28.
• On Tuesday, December 23rd, Suvretta Capital Management, L purchased 50,000 shares of Benitec Biopharma stock. The stock was purchased at an average price of $12.85 per share, with a total value of $642,500.00.
• On Monday, December 22nd, Suvretta Capital Management, L acquired 19,542 shares of Benitec Biopharma stock. The stock was purchased at an average cost of $12.08 per share, with a total value of $236,067.36.
• On Friday, December 19th, Suvretta Capital Management, L acquired 16,384 shares of Benitec Biopharma stock. The shares were purchased at an average price of $11.48 per share, for a total transaction of $188,088.32.
• On Thursday, December 18th, Suvretta Capital Management, L bought 10,215 shares of Benitec Biopharma stock. The stock was purchased at an average cost of $11.24 per share, for a total transaction of $114,816.60.
• On Friday, November 7th, Suvretta Capital Management, L bought 1,481,481 shares of Benitec Biopharma stock. The stock was purchased at an average price of $13.50 per share, with a total value of $19,999,993.50.

Benitec Biopharma Stock Performance

Benitec Biopharma stock opened at $13.49 on Tuesday. The stock has a 50-day simple moving average of $13.55 and a 200 day simple moving average of $13.36. The stock has a market capitalization of $456.77 million, a P/E ratio of -11.15 and a beta of 0.20. Benitec Biopharma Limited has a 52 week low of $9.70 and a 52 week high of $17.15.

Benitec Biopharma (NASDAQ:BNTC) last released its quarterly earnings data on Friday, November 14th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.13. Research analysts forecast that Benitec Biopharma Limited will post -1.48 earnings per share for the current year.

Wall Street Analyst Weigh In

Several equities analysts have commented on BNTC shares. Oppenheimer reiterated an “outperform” rating and issued a $29.00 price objective (down from $35.00) on shares of Benitec Biopharma in a report on Tuesday, September 16th. Zacks Research upgraded shares of Benitec Biopharma from a “strong sell” rating to a “hold” rating in a research note on Friday, November 14th. Weiss Ratings reissued a “sell (d-)” rating on shares of Benitec Biopharma in a report on Wednesday, October 8th. HC Wainwright set a $32.00 price objective on Benitec Biopharma and gave the stock a “buy” rating in a report on Monday, November 24th. Finally, JMP Securities set a $22.00 target price on Benitec Biopharma in a research note on Tuesday, November 4th. Six investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $26.25.

Institutional Trading of Benitec Biopharma

Several hedge funds and other institutional investors have recently bought and sold shares of BNTC. Ameriprise Financial Inc. grew its position in shares of Benitec Biopharma by 40.5% during the 3rd quarter. Ameriprise Financial Inc. now owns 154,414 shares of the biotechnology company’s stock worth $2,166,000 after purchasing an additional 44,489 shares in the last quarter. UBS Group AG boosted its stake in shares of Benitec Biopharma by 458.8% in the third quarter. UBS Group AG now owns 99,941 shares of the biotechnology company’s stock valued at $1,402,000 after buying an additional 82,057 shares during the period. BNP Paribas Financial Markets grew its position in Benitec Biopharma by 44.5% during the third quarter. BNP Paribas Financial Markets now owns 2,937 shares of the biotechnology company’s stock worth $41,000 after buying an additional 904 shares in the last quarter. Russell Investments Group Ltd. bought a new position in Benitec Biopharma during the 3rd quarter worth $79,000. Finally, Vanguard Group Inc. raised its holdings in Benitec Biopharma by 2.4% in the 3rd quarter. Vanguard Group Inc. now owns 992,114 shares of the biotechnology company’s stock valued at $13,919,000 after acquiring an additional 22,948 shares in the last quarter. Institutional investors and hedge funds own 52.19% of the company’s stock.

Benitec Biopharma Company Profile

Benitec Biopharma Ltd (NASDAQ: BNTC) is a clinical-stage biotechnology company developing gene-silencing therapies for serious human diseases. The company’s proprietary DNA-directed RNA interference (ddRNAi) platform is designed to enable sustained expression of small RNA molecules that specifically target and silence disease-causing genes. By integrating RNAi sequences directly into DNA constructs, ddRNAi aims to provide a long-term therapeutic effect from a single administration.

Benitec’s lead programs include development of ddRNAi candidates for chronic hepatitis B virus infection and for certain ocular conditions.